We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-2.9%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.2B
AUM Growth
-$2.13B
Cap. Flow
+$212M
Cap. Flow %
1.6%
Top 10 Hldgs %
51.27%
Holding
122
New
17
Increased
44
Reduced
28
Closed
23

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$853M
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$778M
3
AABA
Altaba Inc
AABA
+$385M
4
PPLI
People Inc
PPLI
+$348M
5
BABA icon
Alibaba
BABA
+$288M

Top Sells

Rank Stock Value
1
RHT
Red Hat Inc
RHT
+$964M
2
APC
Anadarko Petroleum
APC
+$738M
3
ARRY
Array Biopharma Inc
ARRY
+$394M
4
BKNG icon
Booking.com
BKNG
+$128M
5
EFX icon
Equifax
EFX
+$117M

Sector Composition

Rank Sector Weight
1 Healthcare 45.06%
2 Technology 13.07%
3 Communication Services 12.09%
4 Industrials 6.1%
5 Consumer Discretionary 5.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
51
Tvardi Therapeutics
TVRD
$24.8M
$39.3M 0.3%
59,722
+33,296
+126% +$27.7M
S
52
DELISTED
Sprint Corporation
S
$38.5M 0.29%
6,234,186
-4,440,814
-42% -$30.6M
PGNX
53
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$37.2M 0.28%
7,350,000
+1,806,614
+33% +$9.01M
KYNB
54
Kyntra Bio
KYNB
$30.4M
$37M 0.28%
40,000
-28,000
-41% -$30.8M
NXPI icon
55
NXP Semiconductors
NXPI
$56.9B
$35.5M 0.27%
325,000
-105,000
-24% -$10.7M
RC
56
Ready Capital
RC
$311M
$35.1M 0.27%
2,205,132
-38,107
-2% -$578K
FATE icon
57
Fate Therapeutics
FATE
$279M
$34.9M 0.26%
2,250,000
-250,000
-10% -$4.79M
UBER icon
58
PUT
Uber
UBER
$161B
$33.6M 0.25%
+1,102,500
New +$41.5M
EXEL icon
59
Exelixis
EXEL
$13.4B
$30.9M 0.23%
1,750,000
-1,250,000
-42% -$25.3M
AMRN
60
Amarin Corp
AMRN
$298M
$30.3M 0.23%
100,030
-112,470
-53% -$39.3M
ZEAL
61
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$25.6M 0.19%
1,010,000
+10,000
+1% +$226K
DCPH
62
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$25.5M 0.19%
+750,000
New +$22.2M
NVTA
63
DELISTED
Invitae Corporation
NVTA
$25.1M 0.19%
1,300,000
+400,000
+44% +$9.43M
PTCT icon
64
PTC Therapeutics
PTCT
$5.83B
$24.6M 0.19%
726,986
+126,986
+21% +$5.53M
GEN icon
65
Gen Digital
GEN
$17.3B
$24.3M 0.18%
+1,030,000
New +$24M
VCYT icon
66
Veracyte
VCYT
$3.4B
$24M 0.18%
1,000,000
+650,000
+186% +$17.3M
STML
67
DELISTED
Stemline Therapeutics, Inc.
STML
$23.9M 0.18%
2,300,000
+800,000
+53% +$10.5M
MRTX
68
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.4M 0.18%
300,000
-695,000
-70% -$65.2M
CRSP icon
69
CRISPR Therapeutics
CRSP
$5.75B
$23M 0.17%
560,367
+60,367
+12% +$2.88M
TECX
70
Tectonic Therapeutic
TECX
$736M
$21.9M 0.17%
129,167
+42,821
+50% +$9.69M
PVTL
71
DELISTED
Pivotal Software, Inc.
PVTL
$21.3M 0.16%
+1,430,000
New +$17.5M
ONCE
72
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$21.3M 0.16%
220,000
-550,000
-71% -$55.1M
ARWR icon
73
Arrowhead Research
ARWR
$12.3B
$18.3M 0.14%
650,000
-1,350,000
-68% -$40M
PTGX icon
74
Protagonist Therapeutics
PTGX
$9.99B
$18M 0.14%
1,500,000
– –
TCDA
75
DELISTED
Tricida, Inc. Common Stock
TCDA
$15.4M 0.12%
+500,000
New +$16.7M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2019 Portfolio in Review

As of Q3 2019, Thomas Steyer held 122 positions worth $13.2B, down 14% from $15.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer's Q3 2019 filing shows 17 new, 44 increased, 28 reduced and 23 closed positions. Its largest new stake was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M. The largest sale was Red Hat Inc, an estimated $964M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 38% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2019 buy was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M.
  • Thomas Steyer added most to Allergan plc in Q3 2019, an estimated $853M increase.
  • Thomas Steyer's biggest Q3 2019 reduction was Booking.com, cutting an estimated $128M.
  • Thomas Steyer fully exited Red Hat Inc in Q3 2019, selling an estimated $964M.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.2B portfolio in Q3 2019.
  • Thomas Steyer opened 17 new positions and closed 23 in Q3 2019.
  • Thomas Steyer's portfolio value fell 14% quarter-over-quarter to $13.2B.

Based on Farallon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.